MRM Health raises €55 million Series B to advance microbiome-based biotherapeutic product pipeline

Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China

Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)

Giant antibody in humans acts like a brace against bacterial toxins

Protein L is known as a “superantigen” because it can bind antibodies in unusual ways

GSK forays into oncology in India with Jemperli and Zejula

The company is bringing precision therapies for gynaecological cancers

AbbVie announces positive topline results from second Phase 3 UP-AA trial evaluating Upadacitinib

The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study

FDA approves first immunotherapy for recurrent respiratory papillomatosis

Sartorius and Nanotein Technologies partner to advance cell therapy manufacturing

Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally

AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata

The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage

Beta-HPV can directly cause skin cancer in immunocompromised people

cSCC is one of the most common cancers in the U.S. and globally